Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia

P. Mecocci, L. Parnetti, G. Romano, A. Scarelli, F. Chionne, R. Cecchetti, M. C. Polidori, B. Palumbo, A. Cherubini, U. Senin

Research output: Contribution to journalArticlepeer-review

Abstract

Autoantibodies against glial fibrillary acidic protein (GFAP) and S100 protein were measured in sera of patients suffering from vascular dementia (VD), presenile Alzheimer's disease (AD), senile Alzheimer's disease (SDAT) and aged healthy controls by means of ELISA test. VD and SDAT showed the highest levels of both autoantibodies, AD the lowest. From these results a relationship between autoantibody titers and aging seems possible. Dosage of anti-GFAP and anti-SlOO autoantibodies does not appear useful for diagnostic purpose because of the overlap observed among groups. Rather, the presence of these antibodies seems to reflect an alteration of the blood-brain barrier that promotes the access of central nervous system antigens to immunocompetent cells.

Original languageEnglish
Pages (from-to)165-170
Number of pages6
JournalJournal of Neuroimmunology
Volume57
Issue number1-2
DOIs
Publication statusPublished - 1995

Keywords

  • Alzheimer's disease
  • Autoantibody
  • Glial fibrillary acidic protein
  • S100
  • Vascular dementia

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia'. Together they form a unique fingerprint.

Cite this